Mice Model Market Size, Share, Growth Rate, Demands, Trends, Key Players and Forecasts to 2029

The global Mice Model Market in terms of revenue was estimated to be worth $1.5 billion in 2024 and is poised to reach $2.2 billion by 2029, growing at a CAGR of 8.1% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The expansion of the market is primarily propelled by their genetical identity with humans, resulting in greater reproducibility of experimental results. The rising pipeline of novel drug therapies is also supporting the growth of this market.

Download a FREE Sample Report PDF of the Global Mice Model Market Research Report at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308&utm_source=Ganesh&utm_medium=P

Key players in the global mice model market include Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), GemPharmatech (China), Cyagen (US), Shanghai Model Organisms Center, Inc. (China), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan), Ozgene Pty Ltd. (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Harbour BioMed (China), Marshall BioResources (US), genOway (France), Vivo Bio Tech Ltd. (India), ingenious targeting laboratory (US), Janvier Labs (France), Applied StemCell (US), Creative Animodel (US), JOINN Laboratories Co., Ltd. (China), Creative Biolabs (US), Crescendo Biologics (UK), Aragen Life Sciences (India), and PolyGene (Switzerland).

This report categorizes the mice model market to forecast revenue and analyze trends in each of the following submarkets:
By Model Type & Service
• Model Type
o Genetically Engineered Mice
o Hybrid/Congenic Mice
o Outbred Mice

• Service
o Breeding
o Cryopreservation
o Rederivation
o Quarantine
o Other services

By Technology
• CRISPR/CAS9
• Microinjection
• Embryonic Stem cell Injection
• Nuclear Transfer
• Other Technologies

By Therapeutic Area
• Oncology
• Metabolic Diseases
• Immunology
• Neurology
• Cardiovascular Diseases
• Other Therapeutic Diseases

By Application
• Drug Discovery & Development
• Research Application
• Personalized Medicine

By End User
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• CROs & CDMOs

CRISPR/Cas9 segment held a dominant share in the technology segment in the mice model industry
Based on the technology, the mice model market has been segmented into CRISPR/CAS9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies. In 2023, CRISPR/Cas9 accounted for the largest share of the market. This is attributed to its capacity to offer in-depth insights into individual genetic variations, enabling personalized medicine by optimizing drug selection based on unique genetic profiles.

Direct Purchase of the Global Mice Model Market Research Report at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=1308&utm_source=Ganesh&utm_medium=P

The drug discovery & development segment of mice model industry is expected to register fastest growth during the forecast period.
Based on the application, the mice model market has been segmented into drug discovery & development, research application, and personalized medicine. In 2023, drug discovery & development accounted for the largest market share and is expected to achieve the highest CAGR during the projected period. The key drivers of drug discovery & development in the market include their ability of mice model to mimic human physiology and disease pathology. Mice models share genetic, physiological, and behavioral similarities with humans, making them valuable tools for studying disease mechanisms, evaluating drug efficacy, and assessing safety profiles.

North America accounted for the largest share in mice model industry in 2023
Geographically, the mice model market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and the Africa. North America held the dominant share followed by Europe. North America has been a leader in supporting research for the development of innovative in new therapy. Thus, the development of novel therapies and R&D efforts taken by countries such as US and Canada, and rising number of preclinical research projects in the region are contributing to the growth of the North America market.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road Suite 430 Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

MarketsandMarkets was founded in 2009 with a simple, yet powerful, idea - every disruption is inherently the source of game-changing business opportunities. At that time, everybody was talking about disruptive trends such as AI, IoT, 3D printing, nanotech, robotics, etc. but nobody was certain about the business opportunities associated with them. Upon sensing this significant white space, MarketsandMarkets started exploring these emerging and fast-growing opportunities and soon realized that it was part of a much bigger game. We figured out that the B2B economy was just beginning to undergo a dramatic transformation, wherein roughly $25 trillion of new revenue sources would emerge by the end of 2030. So, we embarked on a journey to help B2B companies monetize their play in this phenomenon.

This release was published on openPR.